HANMI PHARM. CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 316,000 KRW | +6.22% |
|
+3.27% | -10.35% |
| Sales 2024 * | 1,627B 1.18B | Sales 2025 * | 1,759B 1.28B | Capitalization | 3,775B 2.75B |
|---|---|---|---|---|---|
| Net income 2024 * | 159B 116M | Net income 2025 * | 183B 133M | EV / Sales 2024 * | 2.45 x |
| Net Debt 2024 * | 208B 152M | Net cash position 2025 * | 9.3B 6.77M | EV / Sales 2025 * | 2.14 x |
| P/E ratio 2024 * |
24
x | P/E ratio 2025 * |
20.3
x | Employees | 2,238 |
| Yield 2024 * |
0.17% | Yield 2025 * |
0.17% | Free-Float | 49.92% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.83% | ||
| 1 week | -2.78% | ||
| Current month | -10.66% | ||
| 1 month | -7.47% | ||
| 3 months | -9.98% | ||
| 6 months | -0.34% | ||
| Current year | -15.60% |
1 week
296 000.00
318 000.00
1 month
296 000.00350 000.00
Current year
296 000.00377 000.00
1 year
256 372.55377 000.00
3 years
214 821.22377 000.00
5 years
197 241.00403 503.08
10 years
60 165.34699 535.98
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Yoon Lim
CEO | Chief Executive Officer | 51 | - |
In-Guk Hwang
CMP | Compliance Officer | 52 | - |
Gwi-Hyun Seo
CTO | Chief Tech/Sci/R&D Officer | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Yoon Lim
CEO | Chief Executive Officer | 51 | - |
Gwan-Sun Lee
BRD | Director/Board Member | 64 | - |
Dong-Cheol Seo
BRD | Director/Board Member | 68 | 17-03-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.03% | 2 M€ | -14.14% | ||
| 0.09% | 3 M€ | -.--% | - | |
| 0.09% | 1 M€ | +3.49% | - | |
| 0.05% | 15 M€ | +8.02% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 316,000 | +6.22% | 40 533 |
| 24-04-17 | 297,500 | -0.83% | 32,860 |
| 24-04-16 | 300,000 | -1.96% | 25,846 |
| 24-04-15 | 306,000 | -3.16% | 27,999 |
| 24-04-12 | 316,000 | +0.96% | 30,282 |
End-of-day quote Korea S.E., April 16, 2024
More quotes
Hanmi Pharm Co Ltd is a Korea-based company principally engaged in the manufacturing and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceuticals segment manufactures and sells tablets, capsules, injections, syrups, powders and raw materials used in the treatment of hypertension, reflux esophagitis, influenza type A and influenza type B virus infections and hyperlipidemia, among others. The Other segment is engaged in the materials processing. The Export segment produces and sells products such as powders and injections, and exports technologies.
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
297,500
KRW
Average target price
408,486
KRW
Spread / Average Target
+37.31%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.60% | 2.73B | |
| +22.28% | 44.1B | |
| +17.11% | 21.97B | |
| +10.54% | 13.27B | |
| +7.61% | 13.22B | |
| +37.32% | 11.36B | |
| -8.53% | 7.07B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.09% | 5.23B |
- Stock Market
- Equities
- A128940 Stock
